Rapid agent expansion signals strong momentum in transforming clinical development with compliant, function-specific intelligence tools

Medable Inc., the leading technology platform for AI-powered clinical development, today launched Agentic AI for research sites to reduce burden and assist principal investigators (PIs) in oversight and monitoring of electronic clinical outcome assessment (eCOA) data. Medable’s newest agent integrates seamlessly within its eCOA system workflows. Released just after Medable’s TMF and CRA agents, its PI Summary Agent continues the company’s rapid rollout of function-specific agentic capabilities and is designed to maximize investigator capacity and accelerate site workflows.

Medable PI Summary Agent continuously monitors participant data from eCOA, providing investigators with an AI-generated participant summary and highlighting the most critical data points while ensuring full access to all underlying data with human-in-the-loop control. It also helps PIs and sponsors by surfacing critical patient data for timely review – ensuring oversight of eCOA data is proactive, transparent, and traceable without disrupting trial operations, site or participant activity.

“Regulators expect satisfactory oversight of remotely captured data, which traditionally forced PIs to manually verify content across multiple reports and systems,” said Dr. Pamela Tenaerts, Chief Medical Officer at Medable. “Our agent centralizes that effort for eCOA data, summarizing participants’ most recent data inputs to make remote oversight seamless.”

Medable’s PI Summary Agent is available now as a part of Medable’s eCOA platform.

Learn more about how the company is strategically leveraging agentic AI technology to drive down operational costs and timelines in clinical research at the SCOPE Summit (Feb 2-5, 2026) in Orlando, FL, Booth #806. Medable’s Andrew Mackinnon will be presenting From Tool to Teammate – Unlocking the Power of AI Agents on Wednesday Feb. 4 at 11:15am.

About Medable

Medable is on a mission to get effective therapies to people faster. Its digital clinical trials platform enhances speed, scale, and patient access in clinical research, accelerating medicines for thousands of conditions without treatment or cure. Awarded Leader in eCOA by Everest Group, Medable’s platform has been deployed in nearly 400 trials in 70 countries and 120 languages, serving more than one million patients globally. Medable is a privately held, venture-backed company headquartered in Palo Alto, California. Learn more at medable.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260128381794/en/

“Regulators expect satisfactory oversight of remotely captured data, which traditionally forced PIs to manually verify content across multiple reports and systems,” said Dr. Pamela Tenaerts, Chief Medical Officer at Medable.